There are pre-clinical proof of concept results for our first...

There are pre-clinical proof of concept results for our first generation CAR-NK therapy (CHM 1301) already:

"CHM 1301 demonstrates the synergies of assets in the Chimeric portfolio, as it combines the recently announced efficacy of CHM 1101, Chimeric’s CLTX CAR T cell therapy1, with the efficacy and off-the-shelf convenience of CHM 02012, Chimeric’s NK cell platform, to create a next generation CLTX CAR NK cell therapy.

CHM 1301 was studied in preclinical in vitro models of human ovarian cancer and pancreatic cancer, demonstrating highly promising efficacy. In ovarian cancer, cell killing was increased up to ~260% as compared to first generation CHM 0201 cells, while in pancreatic cancer cell killing was increased up to 300% as compared to first generation CHM 0201 cells.

The expansion into these new disease areas demonstrates the potential of Chimeric’s CLTX CAR therapies to address additional high-unmet need solid tumour types beyond glioblastoma."
https://www.listcorp.com/asx/chm/chimeric-therapeutics-limited/news/positive-in-vitro-data-for-chm-1301-car-nk-cells-2960822.html

If you like what you see with our CAR therapies (including CDH17 soon) as well as the NK therapies in the clinics, wait for the next step:


https://announcements.asx.com.au/asxpdf/20230815/pdf/05smrbn3djhk2g.pdf&ved=2ahUKEwiL-aCV4eeKAxVN3jgGHbMlG6sQFnoECBcQAQ&usg=AOvVaw36SwkJ0AHID9HZi0W7i5Ca

But I agree with @Steini, money - lack thereof I should say - is the biggest concern here. Management needs to show that they are capable of converting the results to non-dilutive funding, preferrably in the form of a licensing deal to show that people/investors/funds outside of HC can see value in our pipeline as well. Due to the synergy of our various therapiea, that could potentially validate more than one of our platforms at once.